ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

ISA has relocated to brand new Biopartner 5 building

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron